{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-25-000078","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.022818+00:00","generated_at":"2026-05-20T22:32:56.197079+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71","bullets":["Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).","Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.","Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.","Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.","FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-25-000078","json":"https://secwatch.observer/filing/0001613103-25-000078.json","markdown":"https://secwatch.observer/filing/0001613103-25-000078.md","text":"https://secwatch.observer/filing/0001613103-25-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/mdt-20250521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:32:56.197079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4819568666","claim":"Skip Kiil was appointed as EVP and President, Cardiovascular Portfolio at Medtronic plc.","evidence_excerpt":"Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assuming"},{"label":"Role","value":"EVP and President, Cardiovascular Portfolio"}],"fact_type":"executive_change"},{"claim_id":"dc8a5c6e1e","claim":"Sean Salmon departed as EVP and President, Cardiovascular Portfolio at Medtronic plc.","evidence_excerpt":"Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"EVP and President, Cardiovascular Portfolio"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}